Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients
This study is currently recruiting patients.
Sponsored by: | Idun Pharmaceuticals |
---|---|
Information provided by: | Idun Pharmaceuticals |
Purpose
The purpose of this study is to determine if IDN-6556, when given orally, is safe and effective in patients with chronic hepatitis C virus infection.
Condition | Treatment or Intervention | Phase |
---|---|---|
Hepatitis C, Chronic |
Drug: IDN-6556 |
Phase II |
MedlinePlus related topics: Hepatitis; Hepatitis C
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Dose Response Study of a Caspase Inhibitor in Hepatitis C Patients
Primary Outcomes: transamininase changes
Expected Total Enrollment: 200
Study start: July 2004;
Expected completion: May 2005
Last follow-up: March 2005;
Data entry closure: May 2005
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
Exclusion Criteria:
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |